Office of Global Regulatory Operations and Policy
Effective March 31, 2019, FDA will begin operational implementation of an agency reorganization. FDA’s reorganization reflects the agency’s commitment to modernizing its structure to advance its mission to protect and promote public health, and to meet the challenges of rapid innovation across the industries regulated by FDA. The FDA’s reorganization will realign several entities across the agency to promote strategic priorities, and will elevate the role of the centers, offices and field forces.
This organization chart reflects the new structure under which FDA will operate.
The Office of Global Regulatory Operations and Policy (also known as GO) comprises the Office of Regulatory Affairs and the Office of International Programs. The Deputy Commissioner for GO provides executive oversight, strategic leadership, and policy direction to FDA’s domestic and international product quality and safety efforts, including global collaboration, global data-sharing, development and harmonization of standards, field operations, compliance, and enforcement activities. A fuller explanation of FDA Globalization initiatives can be found on the International Programs - Globalization page
- Remarks at the AFDO 2018 Conference, International and Government Relations Committee Meeting
- Remarks for the International Regulatory Convergence Panel
- Mark Abdoo, Acting Deputy Commissioner for Global Regulatory Operations and Policy
- GO-101: An Overview of the Office of Global Regulatory Operations and Policy